Cleared Traditional

RHYS-DAVIES EXSANGUINATOR (K842963) - FDA 510(k) Clearance

Class I General & Plastic Surgery device.

K842963 · Woodville Polymer Engineering, Ltd. · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 1984
Decision
21d
Days
Class 1
Risk

K842963 is an FDA 510(k) clearance for the RHYS-DAVIES EXSANGUINATOR. Classified as Tourniquet, Pneumatic (product code KCY), Class I - General Controls.

Submitted by Woodville Polymer Engineering, Ltd. (Mchenry, US). The FDA issued a Cleared decision on August 17, 1984 after a review of 21 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.5910 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Woodville Polymer Engineering, Ltd. devices

Submission Details

510(k) Number K842963 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received July 27, 1984
Decision Date August 17, 1984
Days to Decision 21 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
94d faster than avg
Panel avg: 115d · This submission: 21d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code KCY Tourniquet, Pneumatic
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.5910
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.